Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company founded in 2007 and headquartered in Chatham, New Jersey. The company is mainly focused on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmunity, and cancer, while its rare disease portfolio comprises TNX-2900 for the treatment of Prader-Willi syndrome. Moreover, Tonix has an infectious disease pipeline that comprises TNX-801, a vaccine to prevent smallpox and monkeypox; TNX-1840 and TNX-1850 that are live virus vaccines based on its recombinant pox vaccine (RPV) platform for COVID-19; TNX-3500, a small molecule antiviral drug to treat acute COVID-19; and TNX-102 SL, a small molecule drug to treat Long COVID, a chronic post-acute COVID-19 condition. In addition, its CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction conditions, including TNX-102 SL, which is in mid-Phase 3 development for the management of fibromyalgia; TNX-1900 that is in development for the prevention of migraine headache; and TNX-1300, a biologic designed to treat cocaine intoxication.

Apart from having a successful pipeline of product candidates, Tonix Pharmaceuticals Holding Corp. has also been involved in several non-dilutive sources to fund its operations. These include grants and contracts from the National Institutes of Health and U.S. Department of Defense, and collaboration agreements with the UT Southwestern Medical Center and Viiv Healthcare. The company has also been awarded several grants from BARDA, a division of the U.S. Department of Health and Human Services, for its investments in vaccines and therapeutics for COVID-19.

In 2020, Tonix Pharmaceuticals Holding Corp. became a public company with its initial public offering on the NASDAQ stock exchange. The company is led by CEO Dr. Seth Lederman, who has had over 28 years of experience in the biopharmaceutical industry. Dr. Lederman spearheaded the company’s strategic shift towards immunology, rare diseases, and infectious diseases and his expertise has led to a total of 13 clinical trials and 5 product candidates. Moreover, the company has published its progress in several peer-reviewed journals and is also supported by five U.S. and international patents. As of 2021, Tonix Pharmaceuticals Holding Corp. employs almost 60 personnel at its Chatham, New Jersey headquarters.